Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells

Zhou, Hongzhuan; Su, Xia; Lin, Lulu; Zhang, Jin; Qi, Qi; Guo, Fangfang; Xu, Fei; Yang, Bing

doi:10.3390/v11080742

Cited by 9 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that in-vitro activity of such drugs as ribavirin, favipiravir, chloroquine, hydroxyquinoline, nitazoxanide, penciclovir and remdesivir against COVID-19 have already been evaluated (Korba et al, 2008 ; Zhou et al, 2019 ). Among them, the remdesivir ( 5 ) exhibited excellent anti-COVID19 activity (EC 50 = 0.77 μM, CC 50 > 100 μM) with the highest selectivity index (SI > 129.87) (Korba et al, 2008 ).…”

Section: Discussionmentioning

confidence: 99%

In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling

Mosayebnia

Bozorgi

Rezaeianpour

et al. 2021

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

The outbreak of the second severe acute respiratory syndrome coronavirus (SARS-CoV-2) known as COVID-19 has caused global concern. No effective vaccine or treatment to control the virus has been approved yet. Social distancing and precautionary protocols are still the only way to prevent person-to-person transmission. We hope to identify anti-COVID-19 activity of the existing drugs to overcome this pandemic as soon as possible. The present study used HEX and AutoDock Vina softwares to predict the affinity of about 100 medicinal structures toward the active site of 3-chymotrypsin-like protease (3Clpro) and RNA-dependent RNA polymerase (RdRp), separately. Afterwards, MOE software and the pharmacophore-derived query methodology were employed to determine the pharmacophore model of their inhibitors. Tegobuvir ( 19 ) and compound 45 showed the best binding affinity toward RdRp and 3Clpro of SARS-CoV-2 in silico, respectively. Tegobuvir -previously applied for hepatitis C virus- formed highly stable complex with uncommon binding pocket of RdRp (E total: −707.91 Kcal/mol) in silico. In addition to compound 45 , tipranavir ( 28 ) and atazanavir ( 26 ) as FDA-approved HIV protease inhibitors were tightly interacted with the active site of SARS-CoV-2 main protease as well. Based on pharmacophore modelling, a good structural pattern for potent candidates against SARS-CoV-2 main enzymes is suggested. Re-tasking or taking inspiration from the structures of tegobuvir and tipranavir can be a proper approach toward coping with the COVID-19 in the shortest possible time and at the lowest cost.

show abstract

Section: Discussionmentioning

confidence: 99%

In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling

Mosayebnia

Bozorgi

Rezaeianpour

et al. 2021

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…Finally, a few interesting future directions exist in treatment that should be examined in a shelter setting. Continuous 24 h monitoring via automated, low cost, noncontact medical devices [ 64 ], fecal transplants [ 65 ], antiviral treatments [ 66 , 67 ], blood transfusions [ 68 ], and more community outreach to encourage early intervention could potentially help save the last 10%–15% of animals in this population. Regardless of these innovations, together, these results demonstrate the imminently practical treatability of canine parvovirus in an animal shelter setting.…”

Section: Discussionmentioning

confidence: 99%

A Decade of Treatment of Canine Parvovirus in an Animal Shelter: A Retrospective Study

Horecka¹,

Porter²,

Amirian³

et al. 2020

Animals

View full text Add to dashboard Cite

Here, we present 11.5 years of monthly treatment statistics showing an overall intake of 5127 infected dogs between June 2008 and December 2019, as well as more detailed datasets from more recent, less protracted time periods for the examination of mortality risk, seasonality, and resource requirements in the mass treatment of canine parvovirus (CPV) in a private animal shelter. The total survival rate of animals during the study period was 86.6% (n = 4438/5127 dogs survived) with the probability of survival increasing to 96.7% after five days of treatment (with 80% of fatalities occurring in that period). A distinct parvovirus season peaking in May and June and troughing in August, September, December, and January was observed, which could have contributed as much as 41 animals peak-to-trough in the monthly population (with a potential, smaller season occurring in October). Low-weight and male animals were at higher risk for death, whereas age was not a significant contributing factor. Treatment time averaged 9.03 h of total care during a seven-day median treatment duration. These findings, taken together, demonstrate that canine parvovirus can be successfully treated in a sustainable manner within a shelter setting using a largely volunteer workforce.

show abstract

“…In the collected cells (approximately 4000 cells per sample), 40 µL of Solution A was added and vortexed for 20 s. After standing at room temperature for 3–5 min, 40 µL of Solution B was added, vortexed for further 30 s. The treated samples were diluted 400 times and stored at −20 °C for further use. Quantitative standard curves were prepared using laboratory-stored pMD-VP2S positive plasmid according to the previously reported method [ 13 ]. For sample quantification, 10 µL SuperReal PreMix Plus (SYBR Green) (TIANGEN, Beijing, China) and 0.2 µM specific primers (VP2-F 5′-CAAATAGAGCATTGGCTTAC-3′ and VP2-R 5′-TCCCATTTGAGTTACACCG-3′) were added to the 3 µL diluted sample, and the total volume was supplemented with water to 20 µL.…”

Section: Methodsmentioning

confidence: 99%

Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells

Su,

Zhou,

Han

et al. 2024

Viruses

Self Cite

View full text Add to dashboard Cite

Canine parvovirus (CPV) is a single-stranded DNA virus that can cause typical hemorrhagic enteritis, and it is one of the common canine lethal viruses. In previous studies, we screened the Food and Drug Administration (FDA)’s drug library and identified nitazoxanide (NTZ), which has anti-CPV capabilities. To investigate the potential antiviral mechanisms, we first reconfirmed the inhibitory effect of NTZ on the CPV by inoculating with different doses and treating for different lengths of time. Then, the differences in the transcription levels between the 0.1%-DMSO-treated virus group and the NTZ-treated virus group were detected using RNA-seq, and a total of 758 differential expression genes (DEGs) were finally identified. Further Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the DEGs revealed that these genes are involved in a variety of biological processes and/or signaling pathways, such as cell cycle, mitosis and cell proliferation and differentiation. A protein–protein interaction (PPI) analysis further identified hub genes associated with cell cycle and division among the DEGs. In addition, the expression levels of some of the enriched genes were detected, which were consistent with the high-throughput sequencing results. Moreover, when the cell cycle was regulated with cell cycle checkpoint kinase 1 (Chk1) inhibitor MK-8776 or Prexasertib HCl, both inhibitors inhibited the CPV. In summary, the transcriptome differential analysis results presented in this paper lay the foundation for further research on the molecular mechanism and potential targets of NTZ anti-CPV.

show abstract

Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells

Cited by 9 publications

References 47 publications

In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling

In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling

A Decade of Treatment of Canine Parvovirus in an Animal Shelter: A Retrospective Study

Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells

Contact Info

Product

Resources

About